Anavex Life Sciences Corp (AVXL)

[georgejjl]

AVXL stock trading volume exceeded 2 million shared traded TODAY 7 February 2023.

Good luck and GOD bless,

[kevindenver]

The Cantor Price target also needs to be put into context that the contract was drawn up in 2018 at below $5. Sometimes 100% targets get met... They will be back in another financing round someday in the far future and the "Strong Buy" will be right back on.


Some ancient history for you:
https://www.sec.gov/Archives/edgar/data/1314052/000161577418006280/s111267_8k.htm

[Twice Worthy]

Very interesting that during the CC that foreign countries drug regulators could be focusing on Anavex and possible approval of Anavex drugs and, Anavec very aware of this ... and the possibility that our FDA would need to play catch-up ... especially, with our desperate FDA approving a new Alzheimers drug causing that causes brains to bleed and patients to die.

[Gator328]

Not bad. I bonds also look attractive, just not as much as last May when the rate was over 9%

[bb8675309]

Anavex Life Sciences Stock Shows Improved Price Strength Rating

https://www.investors.com/news/technology/anavex-life-sciences-stock-hows-improved-price-strength-rating/?src=A00220

[sab63090]

Last Post.........lol

Super strong close.......nice conviction volume!

Pretty impressed with this close and intra-day trading action......

Hope Charlie Duncan would increase his target, but he probably won't...

[Steady_T]

Well, at least on analyst has hit his target. close at $11.75 today. Now that his target has been exceeded what will his next price target be? Up or down?

[georgejjl]

AVXL stock price up 5.76% today!!!

GOD bless,

[longtermbeliever]

not looking good for shorty humm.JUST HOLD ON TIGHT LOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOONGS

[sab63090]

He's the best analyst, an old pro....and I know not easy to impress, so that will be not liked by many......check his record!

Nice comeback, but very impressed with the $XBI and $IBB on where they turned!

We need to see a strong pop over $12 now to meet my target....great volume!

[LakeshoreLeo1953]

I just got 5% on 11 month FDIC CD @5%.
May not appeal to WGT, but as part of a portfolio?

[georgejjl]

Up up and away for AVXL stock.

Good luck and GOD bless,

[LBSR TO DA MOON]

Powell's comments clearly impacted the valuation of nearly every stock index...for about 1/2 hour or so
Looks like Missling's comments must be the reason why AVXL is currently up 3.5% for the day and has added about $32M to its valuation, right? I mean, what else could today's increase be attributed to?

Yea cause Powell's comments impact the valuation of a tiny biotech company.

[Anshu2]

He decided to leave AVXL and be on sidelines. I don't think his reasons for leaving have changed == so, he'll likely remain on sidelines, imo.

[FitzyP33]

Yea cause Powell's comments impact the valuation of a tiny biotech company.

[longtermbeliever]

crazy day but all loongs still in a very good hand.JUST HOLD ON TIGHT LOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOONGS

[LBSR TO DA MOON]

Back in early December 2022, Cantor Fitzgerald's Charles Duncan downgraded AVXL from Overweight to Neutral and lowered his price target down from $16.00 to $11.00. I wonder if he will be making any revisions in the near future...

[georgejjl]

Jerome Powell could be replaced as Chairman of the Federal Reserve for being too conservative with regarding to raising interest rates to tame inflation that is already under control. He should eat ch the money supply.

interest rates affect the stock market and the stock market movement affects AVXL's stock price.

GOD bless,

[boi568]

I am sure that the 2b/3 trial has yielded some complexities. The tipoffs are the combined dose arms (titration/dropout issues?) and the unusual endpoint measurements (to handle nonstandard response curves?). Additionally, Missling has previously noted the genomic study will be used for context, and this morning produced an interesting list of other AD symptoms to be analyzed. So, even as a Phase 3 this is complicated.

[BIOChecker4]

You can’t possibly know that without seeing the analyst’s earnings model and the assumptions he uses.

They make stuff up. Sound familiar?

[georgejjl]

$58 is a very good near term price target from Jones Trading,

GOD bless,

[kund]

Yep

Latest Buy rating with lower price:

https://www.tipranks.com/news/blurbs/anavex-life-sciences-avxl-gets-a-buy-from-jonestrading-2


Earlier rating with $80 price

https://markets.businessinsider.com/news/stocks/anavex-life-sciences-avxl-receives-a-buy-from-jonestrading-1031949314

[BIOChecker4]

I wonder if people realize that not once in all these years has any analyst’s price target on AVXL been hit. Not even close.

The analysts are desperate to bring investment banking business into their firms, especially at a time when the investment banks are struggling.

[BIOChecker4]

“See how may times he said as soon as possible just to answer one simple question, guy don't understand anything about time and it's value.”

I haven’t done so yet but I’m planning on doing so as soon as possible. I’ll be soon, very soon. I promise.

[Anshu2]

Down from $80?!

[LBSR TO DA MOON]

He raised his price target to $80 back in early December 2022. Where did you see $58?

In a report released today, Soumit Roy from JonesTrading maintained a Buy rating on Anavex Life Sciences (AVXL – Research Report), with a price target of $58.00.

[LBSR TO DA MOON]

I guess you were taking a nap between 1:00pm EST - 1:30pm EST...

Umm the S&P and Nasdaq are positive and the DOW is headed there after Powell spoke??

[plexrec]

Bourbon--" Soumit Roy from JonesTrading"--good find--analyst must have liked what he heard at the CC today !! Great !

[Anshu2]

CEO is not all that matters about a company’s fortunes. However terrible CM may be wrt communications, AVXL can still go anywhere depending on the science results.

[Steady_T]

Here is the list of outcomes that have to analyzed, some of which will require a lot of lab time before analysis.

Primary Outcome Measures :
ADAS-Cog (Alzheimer Disease Assessment Scale-Cognition) [ Time Frame: 48 weeks ]
Reduction in cognitive decline assessed from baseline over 48 weeks with ANAVEX2-73 compared to placebo using the Alzheimer Disease Assessment Scale-Cognition (ADAS-Cog)

ADCS-ADL (Activities of Daily Living) [ Time Frame: 48 weeks ]
Reduction in decline of the ability to perform daily activities assessed from baseline over 48 weeks with ANAVEX2-73 compared to placebo using the Activities of Daily Living Scale (ADCS-ADL)


Secondary Outcome Measures :
CDR-SB (Clinical Dementia Rating Scale Sum of Boxes) [ Time Frame: 48 weeks ]
Reduction in cognitive decline assessed from baseline over 48 weeks with ANAVEX2-73 compared with placebo using the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB)

Number of participants with treatment-related adverse events as assessed by CTCAE v4.03 [ Time Frame: 48 weeks ]
Assess the safety and tolerability of ANAVEX2-73 compared to placebo


Other Outcome Measures:
Number of participants with change of brain volume assessed by MRI [ Time Frame: 48 weeks ]
To evaluate the effect of ANAVEX2-73 on structural and Arterial Spin Labeling (ASL) MRI scan assessments characteristic for AD pathophysiology compared to placebo over a 48-week treatment duration

Blood assessment [ Time Frame: 48 weeks ]
Blood assessment from baseline and compared to placebo at +48 weeks: Abeta40, Abeta42, T-tau, NFL, YKL-40, BACE1 concentration

CSF assessment [ Time Frame: 48 weeks ]
Changes in CSF parameters (Abeta40, Abeta42, T-tau, P-tau, NFL, YKL-40, neurogranin, BACE1 concentration) characteristic for AD pathophysiology from baseline and compared to placebo at

+48 weekstreatment differences within subgroups will be performed


Number of participants with pre-specified genetic variants [ Time Frame: 48 weeks ]
AD relevant pre-specified genetic variants will be assessed. Statistical testing of treatment differences within subgroups will be performed

RSCAQ sleep score [ Time Frame: Weeks 0, 4, 12, 24, 36, and 48 ]
To evaluate whether ANAVEX2-73 improves sleep continuity as assessed on a serial basis (weeks 0, 4, 12, 24, 36, and 48) with a questionnaire that assess reported sleep continuity (RSCAQ)

[Steady_T]

Oh go ahead and sell it all. Be safe. Why take a chance on a " liar/truth-hider".

[sumbuysumsell]

Dang. This whole get rich quick thing is taking years. You'd think TGD would want to be more like a Hare for us shareholders. Why the Tortoise moves? It's like he's methodological or something.
LOL.............

[Bourbon_on_my_cornflakes]

In a report released today, Soumit Roy from JonesTrading maintained a Buy rating on Anavex Life Sciences (AVXL – Research Report), with a price target of $58.00.

[abew4me]

Agreed. I believe we are now in an uptrend --vs-- last year where we were in a downtrend.

[rx7171]

In the past we often saw a sell off after these events. Unfulfilled expectations.
Today is different.

[abew4me]

I have...several times.

Not today, unfortunately. But in the past few years I have sold and bought back at a lower price. Got caught with my pants down a couple of times (where I bet the wrong way) so you have to be very careful.

The MMs almost always have the upper hand. They're the experts.

[Kb1123]

So why not sell and make more
Money if you are sure that’s what it is?

[Kb1123]

Umm the S&P and Nasdaq are positive and the DOW is headed there after Powell spoke??

[Bourbon_on_my_cornflakes]

all we need is ONE GOOD WIN

problem is Missling is like the Pittburgh Steelers offense, moves the ball down the field well but cant get it into the end zone.

[Steady_T]

Those two things are the same.

[Bourbon_on_my_cornflakes]

That makes sense for p2 trials, not p3;

there are large gaps between test completion and full readout because Anavex is both conducting clinical trials and wide-ranging, groundbreaking scientific research.

Remember for alz we had a p2a trial that was supposed to work all that out, with the P2b/3 trial for confirmation of efficacy and dose.

Ditto for PD, that was a fishing expedition so of course a long time to analyze is reasonable.

But the current alz results are targeted, and should not take that long.

At least throw us a bone and put out the 50mg top line results.

[abew4me]

Nah. Just the MMs shaking the tree for weak hands.

They move it up quickly and get everyone excited, then take it down and hope that the weak hands sell off. Wash and repeat until you've sold all of your shares to them.

Then they take it higher next month.

[Joseph_K]

Are you proposing a new drinking game?

See how may times he said as soon as possible just to answer one simple question ...?

[McMagyar]

Maybe look at fb group.. see if they had a statistic chart hit..

[LBSR TO DA MOON]

Wow! You actually think the reason AVXL went "off a cliff" is because of Missling? I guess you missed Powell's comments earlier...

Wow. Went off a cliff straight down. This CEO and stock is so predicable. Easy to trade and make money around events.

[kund]

See how may times he said as soon as possible just to answer one simple question, guy don't understand anything about time and it's value.

Christopher Missling

We actually try to do this as soon as possible because we want to share that also with the agencies in the FDA in Europe. So we are really keen to do that as soon as possible. But at this point in time, it's too premature to give guidance on the timing, but you can be assured we do that as soon as possible.

[Bourbon_on_my_cornflakes]

Another enthusiastic share holder lol

Don't you know that questioning Dear Leader is not allowed?

Remember his AVXL sheep are everywhere and could report you for insufficent shareholder enthusiasm.

[FitzyP33]

Wow. Went off a cliff straight down. This CEO and stock is so predicable. Easy to trade and make money around events.

[Joseph_K]

Where did 3-71 come from?

I know 2-73 was bought from the Greek scientist. But 3-71 was developed later, no? By whom? Is Anavex in-house scientific work just on trials, or do they have a hand in finding new molecules?

[nidan7500]

Agree, gbrown...We'll see , but I do expect we(AVXL) will start to get a lot more attention and respect as our results begin to speak and sink in...WW. IMO, Dr.M. is also describing a process for moving fwd.

Working further upstream is a massive strategic change for all/most of BP. IMO, some will "GET IT" , others NOT. IMO, all we need is ONE GOOD WIN with this new upstream focus and OUR MOA will sink in.

It's a LONG story but we are on the point leading a change (w/some friends soon to join, IMO) while the rest are going to be watching w/the Amyloid (FDA) Thesis crowd as AVXL (etal w/friends) results demonstrate the way out of the woods. BUT, the HERD has to WANT TO listen first. That is what we are seeing now, fingers crossed.